[A22-125] Olopatadine/mometasone (allergic rhinitis) – Benefit assessment according to §35a Social Code Book V
Last updated 01.06.2023
Project no.:
A22-125
Commission:
Commission awarded on 29.11.2022 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Airways and respiratory system
Adults and adolescents 12 years of age and older for the treatment of moderate to severe nasal symptoms associated with allergic rhinitis
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| G23-09 | Olopatadine/mometasone furoate (allergic rhinitis) – Addendum to Commission A22-125 | Commission completed |
Federal Joint Committee (G-BA)
2023-06-01 A G-BA decision was published.